Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  I am impressed with Bioscience Valuation's professional approach that enables us to plan future revenues and capacity utilization much better now.

Dr. Folker Ruchatz, SVP Contract Manufacturing Business, Boehringer Ingelheim Biopharmaceuticals GmbH

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Commercial Assessment

Bioscience Valuation's Commercial Assessment covers
  • in-depth analysis of disease market, standard of care and medical need,
  • definition of target product profile (TPP),
  • forecast of incidence and prevalence,
  • detailed analysis of competitors (launched and in development),
  • a pharmacoeconomic assessment,
  • determination of a product's optimal price range and likely market share,
  • if ordered, primary market research,
  • sales forecast until patent expiry.
Core Services - Pharmacoeconomics

An early Pharmacoeconomic Assessment

  • determines a drug's incremental cost - effectiveness ratio (ICER) based on its TPP,
  • shows whether a TPP needs improvement to ensure cost - effectiveness,
  • supports management in determining a drug's market price that will likely get reimbursed.

Case:
A 'top 20' multinational pharmaceutical company asked us to perform commercial assessments for their in-licensing candidates. The client expects comprehensive analyses, adhering to the company's highest quality standards.

Our assessments provide the expected analysis that frees up the client's resources to focus on decision-making and internal communications.